Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (321-330 of 567) with videos related to

Pageof 57
Sort By:
British Journal of Cancer|February 20, 2014
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patientsY Wang, T K Choueiri, J-L Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2015
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinomaLaurence Albiges, André P Fay, Wanling Xie, et al.
Arthritis and Rheumatism|January 31, 2002
An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndromeEbun Aganna, Avraham Zeharia, Graham A Hitman, et al.
The Journal of Antimicrobial Chemotherapy|April 1, 2025
Cross-resistance to 14-, 15- and 16-membered ring macrolides in Salmonella and CampylobacterRuby Singh, Sampa Mukherjee, Lucas B Harrision, et al.
European Urology|June 17, 2022
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective StudiesRebecca E Graff, Kathryn M Wilson, Alejandro Sanchez, et al.
Urologic Oncology|February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503Raman Jay, R R McKay, L Werner, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Soluble PD-L1 as an early marker of progressive disease on nivolumabKathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Diabetes/Metabolism Research and Reviews|August 10, 2000
Family association studies of markers on chromosome 2q and Type 1 diabetes in subjects from South IndiaW B Ogunkolade, A Ramachandran, M F McDermott, et al.
Geobiology|July 6, 2016
Molecular biosignatures reveal common benthic microbial sources of organic matter in ooids and grapestones from Pigeon Cay, The BahamasS S O'Reilly, G Mariotti, A R Winter, et al.
Pageof 57

Showing results (321-330 of 567) with videos related to

Sort By:
Pageof 57
British Journal of Cancer|February 20, 2014
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patientsY Wang, T K Choueiri, J-L Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2015
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinomaLaurence Albiges, André P Fay, Wanling Xie, et al.
Arthritis and Rheumatism|January 31, 2002
An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndromeEbun Aganna, Avraham Zeharia, Graham A Hitman, et al.
The Journal of Antimicrobial Chemotherapy|April 1, 2025
Cross-resistance to 14-, 15- and 16-membered ring macrolides in Salmonella and CampylobacterRuby Singh, Sampa Mukherjee, Lucas B Harrision, et al.
European Urology|June 17, 2022
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective StudiesRebecca E Graff, Kathryn M Wilson, Alejandro Sanchez, et al.
Urologic Oncology|February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503Raman Jay, R R McKay, L Werner, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Soluble PD-L1 as an early marker of progressive disease on nivolumabKathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Diabetes/Metabolism Research and Reviews|August 10, 2000
Family association studies of markers on chromosome 2q and Type 1 diabetes in subjects from South IndiaW B Ogunkolade, A Ramachandran, M F McDermott, et al.
Geobiology|July 6, 2016
Molecular biosignatures reveal common benthic microbial sources of organic matter in ooids and grapestones from Pigeon Cay, The BahamasS S O'Reilly, G Mariotti, A R Winter, et al.
Pageof 57